Associated Papers
Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.
Al-Zoubi RM et al.
Drug Development Research, 2026
Lung cancer-enriched p53 mutants occupy canonical p53 target genes without activating transcription, revealing a distinct loss-of-function behavior.
Tracewell MA et al.
Biorxiv : the Preprint Server for Biology, 2026
Analysis of genetic mutation characteristics in 40 Chinese patients with hepatocellular carcinoma.
Xu S et al.
Genes & Genomics, 2026
AI-Guided Conformational Dynamics of p53 L1 Loop Reveal an Allosteric Switch Regulating DNA Binding and Cancer Hotspots.
Navarro Acero P et al.
Journal of Chemical Information and Modeling, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.
Rustamov R et al.
Virchows Archiv : an International Journal of Pathology, 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.
Tahaney WM et al.
Breast Cancer Research and Treatment, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence.
Chin SI et al.
Journal of Visualized Experiments : Jove, 2025
p53: An Immune Ecosystem Manipulator.
Nian Z et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.
Mohammad AOA et al.
Cancer Biology & Therapy, 2025
Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.
Paulino PJIV et al.
Journal, Genetic Engineering & Biotechnology, 2025
Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology.
Domenico D et al.
Nature Communications, 2025
Resource: A compendium of HLA types and expression in pediatric cancer models.
Guan Y et al.
Iscience, 2025
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition.
Liu K et al.
Communications Biology, 2025
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Feasibility of a ctDNA multigenic panel for non-small-cell lung cancer early detection and disease surveillance.
Casagrande GMS et al.
Molecular Oncology, 2025
High-throughput evaluation of genetic variants with prime editing sensor libraries.
Gould SI et al.
Nature Biotechnology, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Unraveling the Molecular Basis of Extracranial Glioblastoma Metastasis: A Case Report and Literature Review.
Manzano-Benito I et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Scollon S et al.
Jco Precision Oncology, 2025
Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.
Hartner S et al.
Nature Communications, 2025
p53 isoforms have a high aggregation propensity, interact with chaperones and lack binding to p53 interaction partners.
Brdar A et al.
Elife, 2025
Targeted Protein Acetylation Through Chemically Induced Proximity.
Wang WW et al.
Accounts of Chemical Research, 2025
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review.
Abujamous L et al.
The Oncologist, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
Multigene germline and somatic testing for epithelial ovarian cancer in China.
Li L et al.
Npj Precision Oncology, 2025
Patient-derived organoid models of malignant phyllodes tumours for drug sensitivity testing and identification of targeted therapeutic strategies.
Chen J et al.
Journal of Drug Targeting, 2025
GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function.
Anand V et al.
Oncogene, 2025
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.
Skoulidis F et al.
Nature Medicine, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
Molecular Landscape of Metastatic Lung Adenocarcinoma in Bulgarian Patients-A Prospective Study.
Dimitrov G et al.
International Journal of Molecular Sciences, 2025